SLC22A12 and hyperuricemia: Currently, the use of the first three inhibitors for the treatment of gout varies between different countries9, while lesinurad (ZURAMPIC®) is a new URAT1 inhibitor approved in both Europe and the United States for the treatment of hyperuricemia associated with gout in combination with an XOI25.